Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
CAR-T cells therapy Urokinase-type plasminogen activator receptor (uPAR) Different senolytics have been developed in the antibody or small drug fields but nothing regarding senescent cells due to the lack of identification of specific surface targets on these cells 51
Your goals, your health status, your tolerance for side effects, and your budget all factor into the decision
well-tolerated in mice, rats, rabbits, and dogs with no serious organ toxicity.[34][35] Clinical Safety : Mild local irritation possible at injection sites, but no systemic adverse effects reported in trials.[36][37] Potential Risks : Theoretical concerns include pro-angiogenic effects potentially promoting tumor growth, though no evidence supports this in studies.[38] Long-term human data is limited, so monitoring is advised
All protocol-level guidance is based on published data and preclinical evidence cited inline
